Feasibility and safety of local treatment with recombinant human tissue factor pathway inhibitor in a rat model of Streptococcus pneumoniae pneumonia

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Van Den Boogaard, Florry E ^a   Hofstra, Jorrit J ^a   Van 't Veer, Cornelis ^a   Levi, Marcel M ^a   Roelofs, Joris J T H ^a   Van Der Poll, Tom ^a   Schultz, Marcus J ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; ANTICOAGULANT AGENT; LIPOPROTEIN; LIPOPROTEIN-ASSOCIATED COAGULATION INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ARTICLE; BACTERIAL LOAD; BLOOD CLOTTING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG SAFETY; FEASIBILITY STUDY; FIBRINOLYSIS; HISTOPATHOLOGY; LUNG LAVAGE; NEBULIZATION; NONHUMAN; STREPTOCOCCUS PNEUMONIA; TREATMENT OUTCOME; ANIMAL; BLOOD; BRONCHOALVEOLAR LAVAGE FLUID; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; HUMAN; INTRANASAL DRUG ADMINISTRATION; MALE; MICROBIOLOGY; NEBULIZER; PNEUMONIA, PNEUMOCOCCAL; RAT; SPRAGUE DAWLEY RAT;

RATTUS; STREPTOCOCCUS PNEUMONIAE;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION; BRONCHOALVEOLAR LAVAGE FLUID; DISEASE MODELS, ANIMAL; FEASIBILITY STUDIES; HUMANS; LIPOPROTEINS; MALE; NEBULIZERS AND VAPORIZERS; PNEUMONIA, PNEUMOCOCCAL; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84930647412     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0127261     Document Type: Article

References (48)

1. Glas GJ, Van Der Sluijs KF, Schultz MJ, Hofstra JJ, Van Der Poll T, Levi M (2013) Bronchoalveolar hemostasis in lung injury and acute respiratory distress syndrome. J Thromb Haemost 11: 17-25. doi: 10.1111/jth.12047 PMID: 23114008
2. Schultz MJ, Millo J, Levi M, Hack CE, Weverling GJ, Garrard CS, et al. (2004) Local activation of coagulation and inhibition of fibrinolysis in the lung during ventilator associated pneumonia. Thorax 59: 130-135. PMID: 14760153
3. van der Poll T (2008) Tissue factor as an initiator of coagulation and inflammation in the lung. Crit Care 12 Suppl 6: S3. doi: 10.1186/cc7026 PMID: 19105796
4. Wygrecka M, Jablonska E, Guenther A, Preissner KT, Markart P (2008) Current view on alveolar coagulation and fibrinolysis in acute inflammatory and chronic interstitial lung diseases. Thromb Haemost 99: 494-501. doi: 10.1160/TH07-11-0666 PMID: 18327397
5. Rijneveld AW, Weijer S, Bresser P, Florquin S, Vlasuk GP, Rote WE, et al. (2006) Local activation of the tissue factor-factor VIIa pathway in patients with pneumonia and the effect of inhibition of this pathway in murine pneumococcal pneumonia. Crit Care Med 34: 1725-1730. PMID: 16625114
6. Welty-Wolf KE, Carraway MS, Miller DL, Ortel TL, Ezban M, Ghio AJ, et al. (2001) Coagulation blockade prevents sepsis-induced respiratory and renal failure in baboons. Am J Respir Crit Care Med 164: 1988-1996. PMID: 11734456
7. Bastarache JA, Wang L, Wang Z, Albertine KH, Matthay MA and Ware LB (2008) Intra-alveolar tissue factor pathway inhibitor is not sufficient to block tissue factor procoagulant activity. Am J Physiol Lung Cell Mol Physiol 294: L874-L881. doi: 10.1152/ajplung.00372.2007 PMID: 18310227
8. Lwaleed BA, Bass PS (2006) Tissue factor pathway inhibitor: structure, biology and involvement in disease. J Pathol 208: 327-339. PMID: 16261634
9. Choi G, Vlaar AP, Schouten M, Van 't Veer C, van der Poll T, Levi M, et al. (2007) Natural anticoagulants limit lipopolysaccharide-induced pulmonary coagulation but not inflammation. Eur Respir J 30: 423-428. PMID: 17537762
10. Miller DL, Welty-Wolf K, Carraway MS, Ezban M, Ghio A, Suliman H, et al. (2002) Extrinsic coagulation blockade attenuates lung injury and proinflammatory cytokine release after intratracheal lipopolysaccharide. Am J Respir Cell Mol Biol 26: 650-658. PMID: 12034563
11. Welty-Wolf KE, Carraway MS, Idell S, Ortel TL, Ezban M and Piantadosi CA (2001) Tissue factor in experimental acute lung injury. Semin Hematol 38: 35-38. PMID: 11735108
12. Choi G, Hofstra JJ, Roelofs JJ, Rijneveld AW, Bresser P, van der Zee JS, et al. (2008) Antithrombin inhibits bronchoalveolar activation of coagulation and limits lung injury during Streptococcus pneumoniae pneumonia in rats. Crit Care Med 36: 204-210. PMID: 18090375
13. van den Boogaard FE, Brands X, Schultz MJ, Levi M, Roelofs JJ, van 't Veer C, et al. (2011) Recombinant human tissue factor pathway inhibitor exerts anticoagulant, anti-inflammatory and antimicrobial effects in murine pneumococcal pneumonia. J Thromb Haemost 9: 122-132. doi: 10.1111/j.1538-7836.2010.04089.x PMID: 21029363
14. Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, et al. (2003) Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 290: 238-247. PMID: 12851279
15. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344: 699-709. PMID: 11236773
16. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, et al. (2001) Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 286: 1869-1878. PMID: 11597289
17. Honeybourne D (1997) Antibiotic penetration in the respiratory tract and implications for the selection of antimicrobial therapy. Curr Opin Pulm Med 3: 170-174. PMID: 9193864
18. Tuinman PR, Dixon B, Levi M, Juffermans NP, Schultz MJ (2012) Nebulized anticoagulants for acute lung injury - a systematic review of preclinical and clinical investigations. Critical care 16: R70. doi: 10.1186/cc11325 PMID: 22546487
19. van der Poll T, Opal SM (2009) Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet 374: 1543-1556. doi: 10.1016/S0140-6736(09)61114-4 PMID: 19880020
20. Hofstra JJ, Cornet AD, Declerck PJ, Dixon B, Aslami H, Vlaar AP, et al. (2013) Nebulized fibrinolytic agents improve pulmonary fibrinolysis but not inflammation in rat models of direct and indirect acute lung injury. PLoS One 8: e55262. doi: 10.1371/journal.pone.0055262 PMID: 23408962
21. Sandset PM, Abildgaard U, Pettersen M (1987) A sensitive assay of extrinsic coagulation pathway inhibitor (EPI) in plasma and plasma fractions. Thromb Res 47: 389-400. PMID: 3499007
22. Levi M, de Boer JP, Roem D, ten Cate JW, Hack CE (1992) Plasminogen activation in vivo upon intravenous infusion of DDAVP. Quantitative assessment of plasmin-alpha 2-antiplasmin complex with a novel monoclonal antibody based radioimmunoassay. Thromb Haemost 67: 111-116. PMID: 1377412
23. Wunderink RG, Laterre PF, Francois B, Perrotin D, Artigas A, Vidal LO, et al. (2011) Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 183: 1561-1568. doi: 10.1164/rccm.201007-1167OC PMID: 21297074
24. Gunther A, Mosavi P, Heinemann S, Ruppert C, Muth H, Markart P, et al. (2000) Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Comparison with the acute respiratory distress syndrome. Am J Respir Crit Care Med 161: 454-462. PMID: 10673185
25. Rijneveld AW, Florquin S, Bresser P, Levi M, De Waard V, Lijnen R, et al. (2003) Plasminogen activator inhibitor type-1 deficiency does not influence the outcome of murine pneumococcal pneumonia. Blood 102: 934-939. PMID: 12702502
26. Hofstra JJ, Cornet AD, de Rooy BF, Vlaar AP, van der Poll T, Levi M, et al. (2009) Nebulized antithrombin limits bacterial outgrowth and lung injury in Streptococcus pneumoniae pneumonia in rats. Critical care 13: R145. doi: 10.1186/cc8040 PMID: 19740417
27. Choi G, Schultz MJ, van Till JW, Bresser P, van der Zee JS, Boermeester MA, et al. (2004) Disturbed alveolar fibrin turnover during pneumonia is restricted to the site of infection. Eur Respir J 24: 786-789. PMID: 15516673
28. Milbrandt EB, Reade MC, Lee M, Shook SL, Angus DC, Kong L, et al. (2009) Prevalence and significance of coagulation abnormalities in community-acquired pneumonia. Mol Med 15: 438-445. doi: 10.2119/molmed.2009.00091 PMID: 19753144
29. Camerota AJ, Creasey AA, Patla V, Larkin VA, Fink MP (1998) Delayed treatment with recombinant human tissue factor pathway inhibitor improves survival in rabbits with gram-negative peritonitis. J Infect Dis 177: 668-676. PMID: 9498446
30. Carr C, Bild GS, Chang AC, Peer GT, Palmier MO, Frazier RB, et al. (1994) Recombinant E. coli-derived tissue factor pathway inhibitor reduces coagulopathic and lethal effects in the baboon gram-negative model of septic shock. Circ Shock 44: 126-137. PMID: 7600636
31. Creasey AA, Chang AC, Feigen L, Wun TC, Taylor FB Jr. and Hinshaw LB (1993) Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 91: 2850-2860. PMID: 8514893
32. de Jonge E, Dekkers PE, Creasey AA, Hack CE, Paulson SK, Karim A, et al. (2000) Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood 95: 1124-1129. PMID: 10666180
33. Levi M, ten Cate H, Bauer KA, van der Poll T, Edgington TS, Buller HR, et al. (1994) Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest 93: 114-120. PMID: 8282778
34. Moons AH, Peters RJ, ten Cate H, Bauer KA, Vlasuk GP, Buller HR, et al. (2002) Recombinant nematode anticoagulant protein c2, a novel inhibitor of tissue factor-factor VIIa activity, abrogates endotoxin-induced coagulation in chimpanzees. Thromb Haemost 88: 627-631. PMID: 12362234
35. Taylor FB Jr., Chang A, Ruf W, Morrissey JH, Hinshaw L, Catlett R, et al. (1991) Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock 33: 127-134. PMID: 2044206
36. Welty-Wolf KE, Carraway MS, Ortel TL, Ghio AJ, Idell S, Egan J, et al. (2006) Blockade of tissue factor-factor X binding attenuates sepsis-induced respiratory and renal failure. Am J Physiol Lung Cell Mol Physiol 290: L21-L31. PMID: 16100288
37. Cornet AD, Hofstra JJ, Vlaar AP, van den Boogaard FE, Roelofs JJ, van der Poll T, et al. (2011) Nebulized anticoagulants limit coagulopathy but not inflammation in pseudomonas aeruginosa-induced pneumonia in rats. Shock 36: 417-423. doi: 10.1097/SHK.0b013e31822bcef0 PMID: 21897338
38. Enkhbaatar P, Okajima K, Murakami K, Uchiba M, Okabe H, Okabe K, et al. (2000) Recombinant tissue factor pathway inhibitor reduces lipopolysaccharide-induced pulmonary vascular injury by inhibiting leukocyte activation. Am J Respir Crit Care Med 162: 1752-1759. PMID: 11069808
39. Bastarache JA, Sebag SC, Clune JK, Grove BS, Lawson WE, Janz DR, et al. (2012) Low levels of tissue factor lead to alveolar haemorrhage, potentiating murine acute lung injury and oxidative stress. Thorax 67: 1032-1039. doi: 10.1136/thoraxjnl-2012-201781 PMID: 23033361
40. Kipnis E, Guery BP, Tournoys A, Leroy X, Robriquet L, Fialdes P, et al. (2004) Massive alveolar thrombin activation in Pseudomonas aeruginosa-induced acute lung injury. Shock 21: 444-451. PMID: 15087821
41. Levi M, Lowenberg E, Meijers JC (2010) Recombinant anticoagulant factors for adjunctive treatment of sepsis. Semin Thromb Hemost 36: 550-557. doi: 10.1055/s-0030-1255449 PMID: 20632252
42. de Moerloose P, De Benedetti E, Nicod L, Vifian C, Reber G (1992) Procoagulant activity in bronchoalveolar fluids: no relationship with tissue factor pathway inhibitor activity. Thromb Res 65: 507-518. PMID: 1615494
43. Dixon B, Santamaria JD, Campbell DJ (2008) A phase 1 trial of nebulised heparin in acute lung injury. Critical care 12: R64. doi: 10.1186/cc6894 PMID: 18460218
44. Dixon B, Schultz MJ, Hofstra JJ, Campbell DJ, Santamaria JD (2010) Nebulized heparin reduces levels of pulmonary coagulation activation in acute lung injury. Critical care 14: 445. doi: 10.1186/cc9269 PMID: 21067553
45. Choi G, Wolthuis EK, Bresser P, Levi M, van der Poll T, Dzoljic M, et al. (2006) Mechanical ventilation with lower tidal volumes and positive end-expiratory pressure prevents alveolar coagulation in patients without lung injury. Anesthesiology 105: 689-695. PMID: 17006066
46. Papareddy P, Kalle M, Kasetty G, Morgelin M, Rydengard V, Albiger B, et al. (2010) C-terminal peptides of tissue-factor pathway inhibitor are novel host defense molecules. J Biol Chem.
47. Schirm S, Liu X, Jennings LL, Jedrzejewski P, Dai Y, Hardy S (2009) Fragmented tissue factor pathway inhibitor (TFPI) and TFPI C-terminal peptides eliminate serum-resistant Escherichia coli from blood cultures. J Infect Dis 199: 1807-1815. doi: 10.1086/599097 PMID: 19456231
48. Papareddy P, Kalle M, Sorensen OE, Malmsten M, Morgelin M, Schmidtchen A (2013) The TFPI-2 derived peptide EDC34 improves outcome of gram-negative sepsis. PLoS Pathog 9: e1003803. doi: 10.1371/journal.ppat.1003803 PMID: 24339780